Key Takeaways
- In animal studies, BPC-157 improves healing in tendon, ligament, muscle, and gut injury models, and it lowers inflammatory markers.
- Human evidence is minimal. A 2025 systematic review of BPC-157's musculoskeletal research found 35 animal and lab studies and one human study.
- Your dose, delivery route, and treatment length should come from a licensed provider who has reviewed your health history.
BPC-157 is a lab-made peptide that speeds tendon, ligament, and gut healing in animal studies. Some of that holds up. It isn't FDA-approved, and human evidence is limited to a few small pilot studies.
The research is strongest for tendons and ligaments. These tissues heal slowest on their own, which is why BPC-157 comes up so often alongside other peptides for tendon recovery.
What BPC-157 is
BPC-157 (Body Protection Compound-157) is a synthetic peptide of 15 amino acids. Its sequence is based on a protective protein found in human gastric juice, and researchers at the University of Zagreb first described it in the early 1990s.
Animal studies link BPC-157 to tendon repair, gut protection, nerve recovery, and blood vessel growth. Researchers believe it acts on several repair pathways at once rather than one target, which would explain that range.
Human clinical data is still catching up: a 2025 systematic review of the published literature found 35 preclinical studies and exactly one human study across three decades of research.
How BPC-157 works
Three mechanisms show up most often in the research. All three come from cell and animal studies.
Growth hormone receptor signaling
BPC-157 increases growth hormone receptor expression in tendon fibroblasts, the cells responsible for rebuilding connective tissue. That may help explain why it's studied for healing in tissue with naturally poor blood supply. In a rat study on ligament injury, it improved function, strength, and tissue structure over 90 days.
Blood vessel growth
Tendons and ligaments are poorly vascularized, part of why they heal slowly. BPC-157 is studied for improving blood supply to damaged tissue, a mechanism also relevant to gut healing, though it cuts both ways: the same growth-promoting effect has raised an open question about tumor-growth risk that hasn't been resolved.
Inflammatory cytokines
Preclinical studies show BPC-157 lowers levels of pro-inflammatory cytokines, the signaling proteins that drive swelling and pain after an injury.
Benefits of BPC-157: what the evidence shows
Research interest in BPC-157 clusters around three areas, plus an earlier-stage fourth.
- Gut lining support: BPC-157's most documented effects are gastrointestinal. In animal models, it's associated with protecting the gut lining against damage from NSAIDs, alcohol, and stress-induced ulceration, and supporting recovery in colitis and ischemia-reperfusion injury. For people dealing with IBD-like symptoms or gut irritation from heavy NSAID use, this is one of the more researched potential applications, though still primarily in animal models.
- Tendon and muscle healing: This is the application with the most consistent preclinical support behind it: accelerated tendon-to-bone healing, reduced recovery time in animal models, and effects on muscle tear repair, building directly on the fibroblast and collagen mechanisms above.
- Inflammation modulation: BPC-157 doesn't appear to broadly suppress the immune system the way a corticosteroid does. It's studied instead for a role in reducing pro-inflammatory cytokine activity while preserving the acute inflammatory response tissue needs to repair itself, a distinction that matters clinically since blanket immune suppression carries its own risks.
- Nerve protection (earlier-stage research): BPC-157 shows neuroprotective effects in animal models, including peripheral nerve regeneration after transection and functional recovery in models of spinal cord injury and traumatic brain injury.
How long it takes to work
Timing depends heavily on what's being treated. Because published human data is so thin, there's no rigorous study measuring exact response timeframes for any symptom type.
A licensed provider sets a timeline for your specific goal and checks your progress at follow-ups.
Is BPC-157 legal?
BPC-157 isn't FDA-approved for any medical use, and its compounding status has shifted twice since 2023.
| Date | What happened | What it means |
|---|---|---|
| April 2026 | FDA removed BPC-157 from Category 2 | The restriction lifted, but this didn't authorize compounding |
| July 2026 | FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend adding it to the 503A bulks list | This is a recommendation, not a final rule |
Dosing and delivery: why a provider sets the protocol
Once available, a licensed provider will decide the BPC-157 dose, route, and treatment length based on your health history and the tissue you're targeting, then adjust as you respond.
Rebody's planned BPC-157 prescription pen uses a reusable pen and cartridge instead of vials and syringes. It's part of a broader move away from the classic injection. Rebody already offers needle-free peptide formats like nasal sprays, sublingual troches, and gummies for other treatments.
Possible side effects and safety
- Animal studies: Rat and dog studies found no tissue damage in the liver, kidneys, brain, or other organs over six weeks of dosing.
- Human studies: The three small pilot studies published so far reported no adverse effects. However, they involved very few people and had short follow-up periods.
- Long-term use: Long-term use hasn't been studied in humans. Because BPC-157 promotes blood vessel growth, researchers have raised a possible risk for people with undiagnosed cancers. No study has tested this.
These gaps are the reason for medical oversight. A provider reviews your history for risk factors before prescribing and monitors you once you start.
Where BPC-157 fits in your recovery plan
BPC-157 has three decades of encouraging animal research and almost no human trials. Whether BPC-157 fits your situation depends on your specific goals and health history. Start with a clinician who knows both the evidence and your history.
Schedule a consult with Rebody Health to talk through your goals with a licensed provider. You'll learn which treatments are available today and where BPC-157 stands.
Frequently Asked Questions (FAQs):
How long does it take BPC-157 to work?
No human study has measured this. Animal studies tracked tendon and ligament healing over weeks to months, and one rat ligament study ran for 90 days. Because these tissues have limited blood flow, healing is measured in weeks, not days.
Does BPC-157 really work?
In animals, the results are consistent. BPC-157 improved healing in tendon, ligament, muscle, bone, and gut injury models. In people, it's unproven: only three small pilot studies exist, and there are no randomized controlled trials.
Is BPC-157 a growth hormone?
No. BPC-157 is a synthetic peptide fragment, not a hormone. In lab studies, it increases growth hormone receptor expression in tendon cells, which is distinct from increasing growth hormone levels.